Pharmaceuticals Spain

Spain Long-Acting HIV Treatment Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Spain Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Spain · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $46.4 Mn Placeholder estimate
Estimate 2025 $55.1 Mn 1.9% of the global market
Projected 2034 $261.9 Mn 374.9% Adds $206.7 Mn over 9 forecast years
CAGR 2025–2034 18.9% Faster than 86% of 180 Pharmaceuticals markets here
Key players 4
  • Spain is 1.91% of the global market.
  • In Europe, the largest is Germany at $107.9 Mn.
  • Fastest growing: Russia at 19.6% a year.
  • Spain ranks 5th of 6 by size in Europe.

Market size projection

Spain

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$206.7 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, Spain
YearMarket sizeChange that yearSince 2025
2024 (estimate) $46.4 Mn — —
2025 (base) $55.1 Mn +$8.8 Mn —
2026 (forecast) $65.6 Mn +$10.4 Mn +18.9%
2027 (forecast) $77.9 Mn +$12.4 Mn +41.4%
2028 (forecast) $92.7 Mn +$14.7 Mn +68.1%
2029 (forecast) $110.2 Mn +$17.5 Mn +99.9%
2030 (forecast) $131.0 Mn +$20.8 Mn +137.6%
2031 (forecast) $155.8 Mn +$24.8 Mn +182.5%
2032 (forecast) $185.2 Mn +$29.4 Mn +235.9%
2033 (forecast) $220.2 Mn +$35.0 Mn +299.4%
2034 (forecast) $261.9 Mn +$41.6 Mn +374.9%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Spain Long-Acting HIV Treatment Market Analysis at a glance
Market size, 2025$55.1 Mn placeholder estimate
Forecast, 2034$261.9 Mn placeholder estimate
Growth (CAGR), 2025–203418.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsUse, drug and end user (see all)
Key playersViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Regulator in SpainAEMPSSource: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
Active clinical trials7 in SpainSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Spain Long-Acting HIV Treatment Market Analysis Executive Summary

Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.

Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).

Bar chart: Spain Long-Acting HIV Treatment market size, 2024–2034, placeholder estimates. $46.4 Mn in 2024, $55.1 Mn in 2025 and $261.9 Mn in 2034, 18.9% CAGR.
Spain Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Spain Long-Acting HIV Treatment Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.

Competitive Landscape for Long-Acting HIV Treatment Market in Spain

The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in Spain

Long-Acting HIV Treatment in Spain: rules, payment and research

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices.⁠[1] The National Health System (SNS), run by the regions, gives universal public care.⁠[2] ClinicalTrials.gov lists 7 studies on Long-Acting HIV Treatment that are recruiting, active or about to start in Spain.⁠[3] New HIV infections: 3,100 people in 2025, the latest WHO figure for Spain.⁠[4]

[1] Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.

[2] Spanish Ministry of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, New HIV infections (people). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Spain.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Long-Acting HIV Treatment in context

Spain compared

  • New HIV infections: 3,100 people (2025). World: 1.2 million people (2025). 3rd highest of the 5 countries we cover in Europe.[1]
  • Health spending per person: 3,107 US$ per person (2023). World: 1,317 US$ per person (2023). 5th highest of the 6 countries we cover in Europe.[2]
  • Doctors: 4.29 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 3rd highest of the 6 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, New HIV infections (people). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Long-Acting HIV Treatment market in Spain?
Placeholder estimate: about $55.1 Mn in 2025, rising to about $261.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Spain growing?
Placeholder estimate: about 18.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Who regulates Long-Acting HIV Treatment in Spain?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AEMPS, the Spanish Agency of Medicines and Medical Devices. Source: Spanish Agency of Medicines and Medical Devices (AEMPS). Checked 14 Nov 2026.
How is healthcare paid for in Spain?
The National Health System (SNS), run by the regions, gives universal public care. Source: Spanish Ministry of Health. Checked 14 Nov 2026.
How many clinical trials on Long-Acting HIV Treatment are running in Spain?
7 studies are recruiting, active or about to start in Spain, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Spain. Retrieved 12 Nov 2026.
What does WHO report for Spain?
New HIV infections: 3,100 people in 2025, the latest WHO figure. Source: WHO Global Health Observatory, New HIV infections (people). Retrieved 15 Nov 2026.
How many people in Spain are 65 or older?
21.6% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 16 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Spain

See all

Related on hiv and infectious diseases

See the topic